Instructions for CME/NCPD: Complete the pre-test, listen to the
audio and view the slides, complete the post test, complete the
evaluation form and hit submit. You will be asked to enter your name
and email address on the pre-test, evaluation and post-test. If you
close your internet browser without completing the post test, you
will have ONE more opportunity to complete. A score of 70% must be
achieved on the post test to receive continuing education credits.
If you do not pass the post test after two attempts, you will not be
eligible to try again. Once you complete the evaluation form and
score 70% or higher on your post test, you will automatically be
given your certificate.
To print or save your certificate, you will need to click on the
“download” button and either print or save.
This activity is intended for healthcare professionals practicing in
managed care environments.
This activity is supported by
an educational grant from Pfizer
Bladder cancer, also known as urothelial carcinoma, is the ninth
leading cause of cancer death in the United States. According to the
American Cancer Society, there will be 80,470 new cases of bladder
cancer and 17,670 deaths in the United States in 2020. Before the
advent of new treatments in recent years, the basic management of
this illness has remained unchanged for decades. Long-term survival
for people diagnosed with advanced bladder cancer is poor, with
approximately 5% of patients with metastatic bladder cancer
surviving for 5 years or more. As the role of the immune system in
oncogenesis and therapy has become clearer across cancer types, new
approaches emerged with important benefits in metastatic bladder
cancer, which led to the introduction of immune checkpoint
inhibitors. However, when those options fail, options are sparse to
manage this difficult disease. Fortunately for patients with
metastatic bladder cancer, new agents, including antibody-drug
conjugates, have recently emerged for patients who have failed on
immunotherapy and chemotherapy. It is for this reason that medical
directors, oncologists, practicing physicians, nurse case managers
and other healthcare professionals must be educated on these
emerging options and strategies for their implementation into the
treatment paradigm, which will ultimately improve patient outcomes
in the metastatic bladder cancer patient population.
While immunotherapy has revolutionized care for metastatic bladder
cancer, it doesn't work for everyone. Patients who progress with or
fail immunotherapy will need subsequent therapy, and there is
limited data to guide treatment selection. New data from late-stage
clinical trials introduce emerging targeted agents with great
promise in improving outcomes for these patients. As these options
have recently become available and shown the ability to improve
outcomes in patients with this difficult to treat disease, it is
imperative that physician medical directors, oncologists, practicing
physicians, nurse case managers and other healthcare professionals
are brought up to date regarding these novel treatments, so that
they can properly approve and select therapy based on individual
patient characteristics for improved clinical and economic outcomes.
Upon completion of this
activity, participants will be able to:
Identify current unmet clinical and
economic needs in the management of metastatic bladder cancer
and evidence-based recommendations for the care of patients with
Examine recent clinical data on the
safety and efficacy of immune checkpoint inhibitors in the
management of metastatic bladder cancer in the first line
Assess recent evidence on the role
of maintenance immunotherapy in the first line management of
metastatic bladder cancer
Explore the role of sequential
therapy and the differences between upfront treatment and
sequencing strategies with immune checkpoint inhibitors in
metastatic bladder cancer
Identify patients with metastatic
bladder cancer who would potentially benefit from
immunotherapies, in first line maintenance settings or beyond
||Petros Grivas, MD, PhD
Physician, Seattle Cancer Care Alliance
Associate Professor, Division of Medical Oncology
Clinical Director, Genitourinary Cancers Program
University of Washington School of Medicine
has served as a consultant within the past 24 months for
AstraZeneca, BMS, Clovis Oncology, Genentech/Roche,
Merck, Immunomedics, Mirati Therapeutics, Foundation
Medicine, Bayer, Exelixis, Genzyme, GlaxoSmithKline, EMD
Serono, Pfizer, Janssen, Seattle Genetics, and Dyania
Health. He has received grant research funding to his
institution within the past 24 months from Bavarian
Nordic, Clovis Oncology, Debiopharm, Immunomedics,
Merck, Pfizer, QED Therapeutics, GlaxoSmithKline, KureIT
Cancer Research, and BMS. His presentation has been peer
reviewed for any bias.
MD has no real or perceived financial relationships to
Jeremy Williams has no real or perceived financial
relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no real or perceived
financial relationships to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity.
Accreditation & Designation
This activity has been planned and implemented in accordance with
the accreditation requirements and policies of the Accreditation
Council for Continuing Medical Education (ACCME) through the joint
providership of the National Association of Managed Care Physicians
(NAMCP) and American Association of Managed Care Nurses (AAMCN). The
National Association of Managed Care Physicians is accredited by the
ACCME to provide continuing medical education for physicians.
NAMCP designates this enduring material for a maximum of 1 AMA
PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their
participation in the activity.
The American Association of Managed Care Nurses is accredited as a
provider of nursing continuing professional development by the
American Nurses Credentialing Center's Commission on Accreditation.
Nurses who complete this activity and achieve a passing score will
receive 1 hour in nursing continuing professional development.
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
This activity is supported by an educational grant from
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
Click Here To Continue